Aclaris Therapeutics ACRS

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    +$0.00 (+0.00%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Aclaris Therapeutics (ACRS)
    Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $1.83

    • Market Cap

      $197.91 Million

    • Price-Earnings Ratio

      -1.07

    • Total Outstanding Shares

      107.92 Million Shares

    • Total Employees

      64

    • Dividend

      No dividend

    • IPO Date

      October 7, 2015

    • SIC Description

      Pharmaceutical Preparations

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      701 lee road, Wayne, PA, 19087

    • Homepage

      https://www.aclaristx.com

    Historical Stock Splits

    Execution DateSplit Amount
    No Historical Stock Splits

    Cash Flow Statement

    January 1, 2024 to December 31, 2024
    MetricValue
    Net Cash Flow$-15.31 Million
    Net Cash Flow, Continuing$-15.31 Million
    Net Cash Flow From Operating Activities$-20.07 Million
    Net Cash Flow From Financing Activities$74.54 Million
    Net Cash Flow From Investing Activities, Continuing$-69.77 Million
    Net Cash Flow From Financing Activities, Continuing$74.54 Million

    Income Statement

    January 1, 2024 to December 31, 2024
    MetricValue
    Research and Development$33.59 Million
    Basic Earnings Per Share$-1.71
    Net Income/Loss Attributable To Noncontrolling Interest$0
    Other Operating Expenses$124.27 Million
    Cost Of Revenue$2.79 Million
    Income/Loss From Continuing Operations After Tax$-132.06 Million

    Comprehensive Income

    January 1, 2024 to December 31, 2024
    MetricValue
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
    Other Comprehensive Income/Loss$203,000
    Comprehensive Income/Loss Attributable To Parent$-131.86 Million
    Comprehensive Income/Loss$-131.86 Million

    Balance Sheet

    January 1, 2024 to December 31, 2024
    MetricValue
    Noncurrent Assets$94.38 Million
    Noncurrent Liabilities$33.18 Million
    Other Non-current Assets$93.37 Million
    Liabilities And Equity$220.33 Million
    Accounts Payable$4.69 Million
    Equity Attributable To Noncontrolling Interest$0

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about ACRS from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      ⓒ 2025 Financhle. All Rights Reserved.